HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Quote:
Login Free Membership
Search:

Analyst Blog  

AMMD Sells Ovion Technology

Share
By: Zacks Equity Research
October 09, 2009 | Comment(s): 0
Recommended this article (6)
AMMD | CPTS | JNJ | BSX

American Medical Systems
(AMMD) recently announced that it has agreed to sell its female sterilization assets and technology to Conceptus Inc. (CPTS - Snapshot Report).
 
Under the $23.6 million cash deal, Conceptus acquired all patents and intellectual property associated with the Ovion business, which was acquired by American Medical Systems in July 2005. American Medical Systems acquired Ovion Inc. to further broaden its gynecology franchise. Ovion, a pre-commercialization company, developed an office-based technology for the delivery of a permanent birth control solution for women.
 
Conceptus intends to make use of the Ovion technology to develop future versions of its Essure permanent female contraceptive. Essure, a non-incisional permanent birth control method, received approval from the U.S. Food and Drug Administration (FDA) in 2002.
 
Under the terms of the present agreement, Conceptus will not be required to make any royalty payments to American Medical Systems. Furthermore, the transaction releases Conceptus from making any royalty payments. Conceptus was making royalty payments of 3.25 % on sales of Essure to American Medical under a 2003 settlement agreement. The deal is expected to add 5 cents per share to the third quarter earnings of Conceptus due to the release of the royalty obligations under the 2003 agreement.
 
Headquartered in Minnetonka, Minnesota and founded in 1972, American Medical Systems focuses on men's and women's pelvic health. The company's products treated approximately 320,000 patients in 2008. In addition to U.S. sales, the company sells its products in Canada, Asia, Australia, Europe, and South America. Based on product line, men’s health products and women’s health products contributed approximately 44% and 33%, respectively to 2008 revenue. The balance was contributed by benign prostate hyperplasia (BPH) therapies. On a geographic basis, the U.S. and international operations contributed 71% and 29%, respectively, to total 2008 revenue.
 
American Medical Systems competes with Johnson & Johnson (JNJ - Analyst Report) and Boston Scientific Corp. (BSX - Analyst Report).

Read the full analyst report on AMMD

Read the full analyst report on CPTS

Read the full analyst report on JNJ

Read the full analyst report on BSX

 

Please login to Zacks.com or register to post a comment.


Email

Print

Share

Rate Pos

Rate Neg
Attn. Zacks.com Visitors
7 Best Stocks for the Next 30 Days
Get your free Welcome Gifts today*:
 1.  Special Report with best short-term Zacks recommendations from the list that averages a gain of +26% per year
 2.  Our free e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Market Summary May 25, 2012 23:10 pm ET
DJIA 12454.83  -74.92 -0.60%
NASD 2837.53  -1.85 -0.07%
S&P 500 1317.82  -2.86 -0.22%
Partner Center